Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Gossamer Bio (GOSS) over the last 3 years, with Dec 2024 value amounting to $46.1 million.

  • Gossamer Bio's Cash & Equivalents fell 68.62% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 68.62%. This contributed to the annual value of $46.1 million for FY2024, which is 43.49% up from last year.
  • Gossamer Bio's Cash & Equivalents amounted to $46.1 million in FY2024, which was up 43.49% from $32.1 million recorded in FY2023.
  • In the past 5 years, Gossamer Bio's Cash & Equivalents registered a high of $112.0 million during FY2022, and its lowest value of $32.1 million during FY2023.
  • For the 3-year period, Gossamer Bio's Cash & Equivalents averaged around $63.4 million, with its median value being $46.1 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 71.32% in 2023, then surged by 43.49% in 2024.
  • Gossamer Bio's Cash & Equivalents (Yearly) stood at $112.0 million in 2022, then slumped by 71.32% to $32.1 million in 2023, then skyrocketed by 43.49% to $46.1 million in 2024.